News

5 May 2026

CSO Speaks at US National Research Meeting

5 May 2026

CSO Speaks at US National Research Meeting

5 May 2026

CSO Speaks at US National Research Meeting

29 Apr 2026

Financial year 2025 results & SVN-001 strategy refinement

29 Apr 2026

Financial year 2025 results & SVN-001 strategy refinement

29 Apr 2026

Financial year 2025 results & SVN-001 strategy refinement
Solvonis Therapeutics

22 Apr 2026

Solvonis Appoints Water Tower Research
Solvonis Therapeutics

22 Apr 2026

Solvonis Appoints Water Tower Research
Solvonis Therapeutics

22 Apr 2026

Solvonis Appoints Water Tower Research

20 Apr 2026

Trump’s EO positive signal for rapid-acting CNS therapies in the US

20 Apr 2026

Trump’s EO positive signal for rapid-acting CNS therapies in the US

20 Apr 2026

Trump’s EO positive signal for rapid-acting CNS therapies in the US

8 Apr 2026

Second U.S. Patent from PTSD Programme

8 Apr 2026

Second U.S. Patent from PTSD Programme

8 Apr 2026

Second U.S. Patent from PTSD Programme

31 Mar 2026

Solvonis Granted U.S. Patent from PTSD Discovery Programme

31 Mar 2026

Solvonis Granted U.S. Patent from PTSD Discovery Programme

31 Mar 2026

Solvonis Granted U.S. Patent from PTSD Discovery Programme

10 Mar 2026

SVN-114 selected as the lead candidate for PTSD discovery programme

10 Mar 2026

SVN-114 selected as the lead candidate for PTSD discovery programme

10 Mar 2026

SVN-114 selected as the lead candidate for PTSD discovery programme

28 Jan 2026

Expansion of SVN-015 into depression following positive preclinical data

28 Jan 2026

Expansion of SVN-015 into depression following positive preclinical data

28 Jan 2026

Expansion of SVN-015 into depression following positive preclinical data

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

7 Jan 2026

U.S. Patent allowance received for PTSD discovery programme

Load More